Lancet
-
Randomized Controlled Trial Multicenter Study
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Conventional management of Crohn's disease features incremental use of therapies. However, early combined immunosuppression (ECI), with a TNF antagonist and antimetabolite might be a more effective strategy. We compared the efficacy of ECI with that of conventional management for treatment of Crohn's disease. ⋯ AbbVie Pharmaceuticals.